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Purpose. To noninvasively assess liver fibrosis using combined-contrast-enhanced (CCE) magnetic resonance imaging (MRI) and
texture analysis.Materials andMethods. In this IRB-approved,HIPAA-compliant prospective study, 46 adults with newly diagnosed
HCV infection and recent liver biopsy underwent CCE liver MRI following intravenous administration of superparamagnetic
iron oxides (ferumoxides) and gadolinium DTPA (gadopentetate dimeglumine). The image texture of the liver was quantified in
regions-of-interest by calculating 165 texture features. Liver biopsy specimens were stained with Masson trichrome and assessed
qualitatively (METAVIR fibrosis score) and quantitatively (% collagen stained area). Using 𝐿
1
regularization path algorithm, two
texture-based multivariate linear models were constructed, one for quantitative and the other for quantitative histology prediction.
The prediction performance of each model was assessed using receiver operating characteristics (ROC) and correlation analyses.
Results. The texture-based predicted fibrosis score significantly correlated with qualitative (𝑟 = 0.698, 𝑃 < 0.001) and quantitative
(𝑟 = 0.757, 𝑃 < 0.001) histology. The prediction model for qualitative histology had 0.814–0.976 areas under the curve (AUC),
0.659–1.000 sensitivity, 0.778–0.930 specificity, and 0.674–0.935 accuracy, depending on the binary classification threshold. The
predictionmodel for quantitative histology had 0.742–0.950AUC, 0.688–1.000 sensitivity, 0.679–0.857 specificity, and 0.696–0.848
accuracy, depending on the binary classification threshold. Conclusion. CCE MRI and texture analysis may permit noninvasive
assessment of liver fibrosis.
1. Introduction
The ongoing epidemic of Chronic Liver Disease (CLD) is a
major contributor to liver-related mortality and morbidity in
theUnited States.More than 20,000Americans die fromCLD
complications each year [1]. The most common etiologies
for CLD are chronic hepatitis C virus (HCV) infection and
alcoholic hepatitis [2, 3]. Over 4 million Americans are HCV
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 387653, 12 pages
http://dx.doi.org/10.1155/2015/387653
2 BioMed Research International
No contrast Gd SPIO CCE
Figure 1: MR images of liver in 60-year old man with HCV-related cirrhosis. Noncontrast, Gd-only, SPIO-only, and CCE 2D breath-hold
T1-weighted gradient-echo images of cirrhotic liver due to HCV. Abnormal reticular pattern of the liver parenchyma is better visualized on
single-contrast-enhanced (Gd or SPIO) images than on unenhanced image and better visualized on CCE images than on single-contrast-
enhanced images. Gd: gadolinium; SPIO: superparamagnetic iron oxide, and CCE: combined contrast enhanced.
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Figure 2: Combined contrast enhanced (CCE)MR images at various stages of fibrosis. CCEMR images in adults with chronic HCV infection
and histologically determinedMetavir fibrosis stages F0, F1, F2, F3, and F4. Subjectively, the reticular texture of the liver parenchyma becomes
progressively more pronounced with increasing Metavir fibrosis stage.
carriers, but many are asymptomatic and unaware of their
infection [4].
The common pathway in the natural history of CLD,
including chronic HCV infection, is progressive liver fibrosis
and ultimately cirrhosis [5]. Fibrosis indicates cumulative
liver damage, contributes to the development of portal hyper-
tension and hepatic dysfunction, and predicts poor clinical
outcome [6, 7]. Most liver-related mortality and morbidity
occur in the cirrhotic population [8]. Assessment of liver
fibrosis is therefore critical in the management of patients
with CLD.
The current gold standard for fibrosis evaluation is liver
biopsy. The severity of fibrosis due to HCV infection is often
classified using an ordinal scale such as the Metavir system
[9]. However, biopsy is invasive and thus problematic for
frequent monitoring. Moreover, its interpretation is subjec-
tive, leading to inter- and intraobserver variability [10–12].
For these reasons, noninvasive and objective techniques are
under investigation, including fibrosis-specific serum mark-
ers [13, 14], ultrasound elastography [15, 16], magnetic res-
onance (MR) elastography [17–19], diffusion weighted MR
imaging [20–22], and single-contrast-enhanced MR imaging
[23–25].
Another promising MR imaging-based technique is
combined-contrast-enhanced (CCE) MR imaging [26]. This
technique exploits the complementary effects of positive con-
trast enhancement by gadolinium-chelates (Gd) and negative
enhancement by superparamagnetic iron oxide (SPIO)
agents. Compared to noncontrast, Gd-enhanced, or SPIO-
enhanced images, CCE images better depict the reticular
signal abnormalities associated with fibrosis as shown in
Figure 1 [27]. The conspicuity of this pattern appears to
parallel histologic fibrosis severity (Figure 2) suggesting that
liver fibrosis can be assessed by the severity of the “texture”
abnormality.
The potential role of texture analysis in liver fibrosis
assessment was previously explored in retrospective studies
using qualitative [26] and quantitative [26, 28–30] texture
analysis.The purpose of this prospective study was to provide
proof-of-concept that quantitative texture analysis usingCCE
MR imaging may permit noninvasively assess liver fibrosis in
adults with HCV infection using CCE MR imaging.
2. Method and Materials
2.1. Study Design and Subjects. This prospective, cross-
sectional, observational clinical study was approved by an
institutional review board and isHIPAA-compliant. Potential
eligible subjectswere referred for researchMR imaging exam-
ination from hepatology clinics at our institution. Written
informed consents were obtained. Selection criteria are listed
in Table 1. Patient recruitment was stratified according to the
fibrosis severity at liver biopsy and continued until at least five
subjects in each fibrosis severity category (per clinical biopsy
reports) were enrolled.
2.2. Liver Biopsy. Subjects had a percutaneous 16-gauge
needle-core biopsy of the right hepatic lobe for clinical care by
the referring hepatologists. Specimens were processed in
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Table 1: Selection criteria.
Inclusion criteria Exclusion criteria
(i) Age >18 years
(ii) Newly diagnosed HCV infection, without clinically
overt cirrhosis
(iii) Recent or planned biopsy1
(iv) Willing and able to undergo CCE MRI exam within
30 days of biopsy
(v) Willing and able to undergo phlebotomy for
estimated GFR determination within 30 days of biopsy
(i) Estimated GFR <60mL/mL (𝑁 = 0 potential subjects)
(ii) Imaging not performed within 30 days of biopsy (𝑁 = 2)
(iii) Nondiagnostic biopsy or trichrome slide unavailable (𝑁 = 2)
(iv) Contraindication to MR exam (𝑁 = 1)2
(v) Lack of intravenous access (𝑁 = 1)
(vi) History of severe allergic reaction or anaphylaxis (𝑁 = 0)
(vii) History of liver diseases other than HCV including iron overload (𝑁 = 0)
(viii) Severe claustrophobia (𝑁 = 0)
(ix) Pregnant or nursing mother (𝑁 = 0)
1Biopsies were performed for clinical care. 2Due to intraorbital shrapnel. GFR: glomerular filtration rate. Parenthesis () contains the number of potential
subjects excluded for the criterion.
the pathology department per routine protocol, including
Masson-trichrome staining. Clinical biopsy reports were
generated by staff pathologists. Each clinical report included
assessment of fibrosis severity (none, mild, moderate, severe,
and cirrhosis); the clinically reported fibrosis severity was
used for the block recruitment but not analyzed.
2.3. Qualitative and Quantitative Scoring of Histology. The
trichrome-stained slides were further evaluated for research
purposes. The entire slides were digitized using an APERIO
ScanScope scanner (Aperio Technologies, Inc., Vista, CA).
The digitized images were viewed using the Aperio Image-
Scope software and the fibrosis severity was scored qualita-
tively by histomorphology and quantitatively by digital image
analysis.
Qualitative scoring was performed independently by
three pathologists with expertise in liver pathology (MRP,
HM, and ZG). Without knowledge of clinical, MR imaging,
or quantitative histology findings, each reader reviewed the
digitized histology images, subjectively assessed the adequacy
of each specimen, and assigned to each specimen a Metavir
fibrosis score, F0–F4.The readers were blinded to each other’s
scores. Other histology features (e.g., necro-inflammation,
steatosis, iron)were not recorded. To assess adequacy of spec-
imen, one pathologist (MRP) counted the number of portal
triads within each noncirrhotic specimen; portal triads were
not counted in cirrhotic specimens due to architectural dis-
tortion. The total length of each specimen was recorded.
Quantitative scoring was performed by a hepatology
research scientist (KI) using ImageScope software analysis
tools, without knowledge of the clinical, MR imaging, or
qualitative histology findings. Staining variability was cor-
rected by digitally adjusting color saturation. Total specimen
area was manually segmented, and the blue-stained pixels
(representing collagen) were segmented using manual inten-
sity thresholding. Percent (%) collagen was calculated as the
ratio of blue-stained to total specimen pixels.
2.4. MR Imaging. Subjects received SPIO (ferumoxides,
Feridex, BayerHealthCare Pharmaceuticals,Wayne, NJ) con-
tinuous intravenous infusion (0.5mL/kg) diluted in 100mLof
5% dextrose solution, passed through a 5-𝜇m filter at 2–
4mL/min over 30 minutes per manufacturer’s instructions.
Thirty minutes after completion of SPIO infusion, sub-
jects were scanned supine in a superconducting MR whole
body system at 3T (GE Signa EXCITE HD, GE Med-
ical Systems, Milwaukee, WI), with an 8-channel torso
phase-array coil and a dielectric pad centered over the
liver. Gadolinium-DTPA (gadopentetate dimeglumine, Mag-
nevist, Bayer HealthCare Pharmaceuticals, Wayne, NJ) was
injected intravenously (0.1mmol/kg). Using a 2D chemically
fat-saturated fast spoiled gradient-recalled echo (FSPGR)
sequence without parallel imaging, four sets of axial CCE
images of the liver were acquired during separate 18–28
second breath-holds, 4–10 minutes after Gd injection. In this
6-minute window, enhancement of the liver by the two agents
(SPIO and Gd) is subjectively constant according to our
clinical experience of CCEMR imaging in cirrhotic and non-
cirrhotic livers; moreover, the T1- and T2∗ shortening effects
of gadopentetate and ferumoxides in liver may be assumed
stable over this period from the known liver clearance rates of
these agents [31–33]. The four image sets were acquired to
help ensure that at least one set was free of visible motion
artifacts. Imaging parameters included TR 100ms, TE 6ms,
FA 70∘, slice thickness 4mm, interslice gap 4mm, number of
slices 5, and bandwidth 130Hz/pixel. Two of the four image
sets were acquired with 384 × 224 and two with 384 × 256
matrix. Field-of-view was adjusted to accommodate body
habitus and breath-hold capacity. These parameters were
selected to provide simultaneous T1- and T2∗-weighting to
exploit Gd- and SPIO-enhancement, respectively; adequate
signal-to-noise ratio; high spatial resolution; and relatively
short acquisition time. The Food and Drug Administration
(IND number 75,579) approved off-label use of Magnevist-
Feridex combined contrast for this research study.
2.5. Image Processing and Texture Analysis. A radiology resi-
dent (TY) and a trained research assistant (CC) analyzed the
CCE images without knowledge of clinical or biopsy findings.
From the four CCE image sets, the set with the highest resolu-
tion and subjectively least motion artifact was selected. Rep-
resentative CCE images of the liver (1–5 sections per subject)
were exported in DICOM format. Using MATLAB (Math-
works, Natick, MA), a total of five nonoverlapping rectangu-
lar regions-of-interest (ROIs) of size >100mm2 were placed
per subject within areas of subjectively uniform texture
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in the right hepatic lobe (Couinaud segments IV–VIII),
avoiding artifacts, bile ducts, and vessels. EachROI imagewas
standardized by rotating to the Cartesian coordinate system
with zero tilt-angle, interpolating to 0.5mm/pixel resolution,
removing bilinear spatial trend of signal intensities, and
scaling to 0-1 intensity range.
Gradient and Laplacian transformations (1st and 2nd
spatial derivatives) were applied to each standardized ROI
to generate additional “edge-enhanced” and “zero-crossing”
texture patterns. For each untransformed (original) and
transformed (gradient, Laplacian) ROI, 55 texture features
were calculated as detailed in the supplementary materi-
als available online at http://dx.doi.org/10.1155/2014/387653.
These texture features represented five texture feature classes:
pixel intensity histogram, Gaussian mixture model, auto-
correlation, cooccurrence matrices, and Voronoi polygons.
These classes were selected based on the expected imaging
characteristics of fibrosis texture, as explained in the supple-
mentary materials. For each subject, the texture features were
averaged across the five ROI’s to generate a set of 165 average
texture features.
2.6. Statistical Analyses
2.6.1. Comparison of Histologic Scores. For each subject, the
average, standard deviation (STD), and range of the Metavir
scores of the three pathology readers were calculated. The
interreader agreement was assessed by intraclass correlation
coefficient (ICC, two-way analysis for precise agreement) and
their 95% confidence intervals (CIs) were calculated. ICCwas
also calculated for each pair of readers. The average Metavir
scores of the three readers were compared to %-collagen
scores using Pearson correlation analysis.
2.6.2. Comparison of Texture and Histology. A biostatistician
(TW) performed statistical analysis using the 165 texture
features to predict qualitative (Metavir) and quantitative (%-
collagen) fibrosis scores. A path-following algorithm for 𝐿
1
regularized linear model called GLM-path [34] with a Gaus-
sian link (i.e., linear regression) was used to identify the
optimal linear model of texture features that minimized the
fibrosis prediction error for each number of predictors (i.e.,
features). The optimal number of predictors was determined
by Akaike Information Criterion (AIC) [35]. Using the
qualitative and quantitative fibrosis scores as the reference,
two texture-based fibrosis prediction models were con-
structed, respectively. For each subject, the predicted quali-
tative (Metavir) and quantitative (%-collagen) fibrosis scores
were calculated using respective prediction models.
Pearson’s correlation was used to evaluate the strength of
the relationship between the predicted and histologic scores.
Additionally, the performance of each prediction model
for dichotomized classification was assessed using receiver-
operating-characteristics (ROC) analysis using the average
histologically determined Metavir score as the reference
standard. At each of four classification thresholds (Metavir F1,
F2, F3, and F4 for qualitative scoring; 5, 10, 15, and 20%
collagen for quantitative scoring), the classification accuracy,
sensitivity, and specificity (and their CIs) were calculated at
the predicted fibrosis score cutoff value that maximized the
sum of sensitivity and specificity.
The regularization employed by the GLM-path algorithm
is designed to minimize prediction error over independent
validation datasets [34]. Therefore no dedicated validation
procedure was performed in this proof-of-concept study.
However, the algorithm may not necessarily minimize the
prediction error of the test dataset itself; thus, some degree of
mismatch between the predicted and actual fibrosis scores is
expected.
3. Results
3.1. Subjects. BetweenAugust 2007 andMarch 2009, 52 newly
diagnosed HCV-positive adults (age 51.2±6.3 years, 38 male,
12 female) with recent or planned liver biopsy were recruited
for CCE imaging. Six subjects were excluded (Table 1). The
remaining 46 subjects formed the study group. All subjects
completed the MR examination without serious adverse
effects. At least one CCE image set was subjectively adequate
in quality for further image analyses in each subject.
3.2. Qualitative versus Quantitative Histology. Examples of
biopsy specimens are shown in Figure 3. The histology
specimen’s average ± STD [range] of the total length and the
number of portal triads were 21.9 ± 9.8mm [6.7–44.2] and
14.2 ± 6.0 [4–28], respectively.
Figure 4(a) shows the histogram of qualitative Metavir
scores assigned by the three readers. The 3-reader agreement
was good with ICC of 0.772 (95% CI [0.653–0.859]). Pairwise
ICCs were 0.727, 0.768, and 0.831, depending on the reader
pairs. All readers agreed that all biopsy specimens were
adequate.
Figure 4(b) shows the histogram of quantitative %-
collagen rounded to the nearest 5%.Over half the subjects had
rounded %-collagen ≤5%. As shown in Figure 5 the relation-
ship between the qualitative (average Metavir) and quantita-
tive (%-collagen) scores was curvilinear, as has been observed
by others [36, 37]. Log-linear plot of quantitative (𝑦-axis) and
qualitative (𝑥-axis) scores demonstrated significant linear
correlation with Pearson’s 𝑟 = 0.81 (𝑃 < 0.001).
3.3. Image Texture versus Histology. The liver image textures
of representative subjects are shown in Figure 6 with their
respective qualitative (Metavir) and quantitative (%-collagen)
scores.
Using qualitative histology as the reference, GLM-path
analysis identified a set of 6 texture features predictive of
Metavir fibrosis scores (Table 2). As shown in Figure 7(a), the
Metavir score predicted by a 6-feature model linearly corre-
lated with the averageMetavir scores of the three readers with
𝑟 = 0.698 (𝑃 < 0.001). Table 3 summarizes the ROC analysis
results at each classification threshold. AUCs were 0.814–
0.976, sensitivities 0.659–1.000, specificities 0.778–0.930, and
accuracies 0.674–0.935, depending on the classification
threshold.
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Figure 3: Histologic assessment of liver HCV-related fibrosis. Liver biopsy specimen from subjects with chronic HCV infection, stained with
Masson-trichrome. F0 (absent fibrosis), F1 (stellate enlargement of portal tracts), F2 (enlarged portal tracts with rare septa), F3 (numerous




















































Figure 4: Fibrosis severity distribution.The study group’s histograms byMetavir fibrosis score (left) and%-collagen (right).Themost common
Metavir fibrosis score was F1 or F2 depending on the reader. Nine subjects (19%; 9/46) had a score of F4 (cirrhosis) from at least one reader.
%-collagen is rounded to the nearest 5%.
Using quantitative histology as the reference, GLM-path
analysis identified another set of 6 texture features predic-
tive of %-collagen scores (Table 4). As shown in Figure 5
(LEFT) the%-collagen score predicted by the 6-featuremodel
linearly correlated with %-collagen score of histology with
𝑟 = 0.757 (𝑃 < 0.001). Table 5 summarizes the ROC analysis
results at threshold values at 5, 20, 15, and 20% fibrosis.
AUCs were 0.742–0.950, sensitivities 0.688–1.000, specifici-
ties 0.679–0.857, and accuracies 0.696–0.848, depending on
the classification threshold.
Identified texture features were similar but not identi-
cal between qualitative and quantitative prediction models
(Tables 2 and 4). Two classes of texture features were common
to both Gaussian-mixture model and Voronoi polygons. One
class of texture features (pixel intensity histogram) was pre-
dictive only for qualitative scores. Texture features of both
untransformed and transformed ROI images were found to
be predictive. For illustration purposes, these texture classes
derived from a ROI in a cirrhotic subject are shown in
Figure 8.
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Figure 5: Comparison between quantitative versus qualitative histology. Average Metavir of 3 pathology readers versus (a) raw %-collagen
(b) and natural logarithm of %-collagen. As shown in (a), the relationship between quantitative and qualitative histology scores is curvilinear.
Pearson’s correlation coefficient (𝑟) of plot B is 0.81, with 𝑃 < 0.001.
Table 2: Fibrosis prediction model parameters (texture versus Metavir).
Source image Texture class Texture feature
1 Original Pixel intensity histogram Mean pixel intensity
2 Original Gaussian mixture model STD of the lower intensity pixels
3 Original Gaussian mixture model AIC of two-Gaussian fit/AIC of single-Gaussian fit
4 Original Voronoi polygons STD of the 1st order inertial moment
5 Gradient Voronoi polygons Mean of the 2nd order inertial moment
6 Laplacian Pixel intensity histogram Mode/interquartile range
Six most predictive texture features, from strongest to weakest. Keys: STD: standard deviation, AIC: Akaike Information Criterion, inertial moments:
mathematical description the shape/area of the Voronoi polygons (see supplementary materials).
Table 3: Receiver operating characteristics (texture versus Metavir).
Classification Cutoff Area under curve Sensitivity Specificity Accuracy
F <1 versus F ≥1 1.805 0.814 [0.654 0.975] 0.659 [0.513 0.804] 0.800 [0.449 1.000] 0.674 [0.524 0.797]
F <2 versus F ≥2 1.916 0.889 [0.783 0.994] 0.895 [0.757 1.000] 0.778 [0.621 0.919] 0.826 [0.686 0.916]
F <3 versus F ≥3 2.060 0.862 [0.701 1.000] 0.778 [0.506 1.000] 0.784 [0.651 0.916] 0.783 [0.615 0.867]
F <4 versus F = 4 2.174 0.976 [0.855 1.000] 1.000 [0.907 1.000] 0.930 [0.854 1.000] 0.935 [0.788 0.974]
Cutoff: the operating point on the ROC curve closest to (0, 1), the point of maximum sensitivity and specificity. [ ]—95% confidence interval. The mismatch
between the texture-based cutoff and the histologic classification threshold is expected (see text).
4. Discussion
This study prospectively assessed liver fibrosis in HCV-
infected adults noninvasively using quantitative texture anal-
ysis ofCCEMR images. Liver biopsywas used as the reference
standard. Fibrosis severity was scored qualitatively (Metavir)
and quantitatively (%-collagen). The study design closely
simulated a typical clinical situation, in which a newly diag-
nosed HCV-positive patient without clinically overt cirrhosis
requires assessment of liver fibrosis.
We utilized a CCE MR imaging technique, in which
SPIOs and an extracellular Gd-based agent are administered
sequentially. Prior studies suggested complimentary effects of
SPIO and Gd for visualizing fibrosis. SPIOs accumulate by
phagocytosis in Kupffer cells in the hepatic lobules, causing
T2∗-related negative enhancement. Extracellular Gd-based
agents such as Gd-DTPA distribute to the interstitial space
of the fibrotic perilobular septa, causing T1-related positive
enhancement. The result is a linear meshwork of high-signal
perilobular septa against a background of low-signal lobules,



























Figure 6: Regions-of-interest on CCE MR images in four subjects. Regions-of-interest drawn on CCE MR images in four representative
subjects. Average Metavir (and individual reader METAVIR) and %-collagen scores are shown. Subjectively, high-signal reticular texture
becomes increasingly conspicuous and disorganized with increasing Metavir and %-collagen scores. CCE: combined contrast enhanced.
Table 4: Fibrosis prediction model parameters (texture versus %-collagen).
Source image Texture class Texture feature
1 Original Gaussian mixture model STD of the lower intensity pixels
2 Original Voronoi polygons Mean of the 2nd order inertial moment
3 Original Voronoi polygons STD of the 1st order inertial moment
4 Gradient Voronoi polygons Mean of the 2nd order inertial moment
5 Gradient Gaussian mixture model STD of the lower intensity pixels
6 Laplacian Voronoi polygons Mean of the 3rd order inertial moment
Six most predictive texture features, from strongest to weakest. Keys: STD: standard deviation, AIC: Akaike Information Criterion, inertial moments:
mathematical description the shape/area of the Voronoi polygons (see supplementary materials).
Table 5: Receiver operating characteristics (texture versus %-collagen).
Classification Cutoff Area under curve Sensitivity Specificity Accuracy
<5% versus ≥5% 9.315 0.806 [0.680 0.932] 0.688 [0.527 0.848] 0.857 [0.674 1.000] 0.739 [0.592 0.850]
<10% versus ≥10% 9.807 0.742 [0.589 0.895] 0.722 [0.515 0.929] 0.679 [0.506 0.852] 0.696 [0.547 0.815]
<15% versus ≥15% 10.500 0.894 [0.758 1.000] 0.900 [0.714 1.000] 0.750 [0.609 0.891] 0.783 [0.638 0.884]
<20% versus ≥20% 11.234 0.950 [0.826 1.000] 1.000 [0.907 1.000] 0.825 [0.707 0.943] 0.848 [0.686 0.916]
Cutoff: the operating point on the ROC curve closest to (0, 1), the point of maximum sensitivity and specificity. [ ]—95% confidence interval. The mismatch
between the texture-based cutoff and the histologic classification threshold is expected (see text).
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Figure 7: Texture versus histologic fibrosis scores. (a)The correlation between the texture and qualitative histology score (averageMetavir) is
statistically significant with 0.698 (𝑃 < 0.001) with best-fit line of slope 1.546 and intercept 0.186. (b) Box-plot of texture score versus rounded
average Metavir. Spearman’s correlation is significant at 𝜌 = 0.635 (𝑃 < 0.001). (c)The correlation between texture and quantitative histology
score (percent-fibrosis) is statistically significant with 0.767 (𝑃 < 0.001), with best-fit line of slope 0.355 and intercept 6.636. The nonunit
slope and nonzero intercept are attributable in part to the regularization procedure employed by the GLM-path algorithm (see text).
producing a reticular texture pattern that subjectively
becomes more conspicuous with increasing fibrosis severity
[26, 27].
We found that CCE MR image texture of the liver can be
objectively quantified to predict fibrosis severity. The abnor-
mal texture was detectable at early fibrosis stage, for example,
F > 2 Metavir score or >15%-collagen with accuracy of
0.826 and 0.783, respectively. The predicted fibrosis scores
correlated with but did not exactly match the corresponding
histologically determined scores. The imperfect agreement
between predicted and actual fibrosis scores is likely due to
three factors: intrinsic inaccuracy of the texture-based tech-
nique used in our study, expected mismatch due to the reg-
ularization procedure employed by GLM-path (explained
earlier), and intrinsic inaccuracy of liver biopsy as a reference
standard (explained later).
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Figure 8: Illustrative examples of texture feature classes for fibrosis prediction. A 54 year-old female with cirrhosis. (c) Standardized regions
of interest (ROI) images, without transformation (raw), with gradient and Laplacian transformations. (b) Corresponding pixel intensity
histogram and its Gaussian mixture model fit with two normal populations. (a) Voronoi polygons constructed on the corresponding ROI
images.These texture classes were found to be predictive of liver fibrosis on CCE images (see text). For each texture class (intensity histogram,
Gaussianmixture, and Voronoi polygons), relevant statistics were calculated as detailed in supplementary materials and were used for fibrosis
prediction.
Gaussian mixture models and Voronoi polygons were
found to be predictive texture classes by both qualitative and
quantitative histology prediction models. This is consistent
with the postulated complimentary effects of SPIO and Gd
producing the reticular enhancement pattern in fibrotic liv-
ers. A Gaussian mixture model fits two normal distributions,
each with its own mean and variance, to the overall pixel
intensity histogram. On a CCE image, the liver contains two
populations of pixels, one comprised of low-signal SPIO-
containing pixels devoid of fibrosis and the other of high-
signal Gd-containing pixels in fibrotic septa. With progres-
sion of fibrosis, the proportion of high-signal Gd-containing
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pixels (i.e., fibrosis) increases and, therefore, the pixel inten-
sity histogram is better fitted by a mixture of two Gaussian
distributions than a single Gaussian. The Voronoi polygon
algorithm generates a tessellation of polygons that “carves”
the liver parenchyma into low-intensity nodules, thereby
objectively modeling the reticular texture seen subjectively in
progressive fibrosis.
Another MR-based technique, MR elastography (MRE),
is increasing in popularity and availability for noninvasive
assessment of liver fibrosis. This technique measures the
biomechanical stiffness of the liver, which increases as a
consequence of fibrosis [38]. In a retrospective study inHCV-
infected population [39], the reported AUC, sensitivity, and
specificity of MRE in detecting clinically significant fibrosis
(F ≥ 2) was 0.986, 0.885, and 1.00, respectively, similar to
slightly higher than those of the CCE texture method. How-
ever, texture-basedmethodsmay have a theoretical advantage
of more direct visualization of fibrosis while MRE measures
the tissue biomechanical sequela of fibrosis. Another practical
advantage of texture-basedmethods is that they can be imple-
mented on any clinical scanner using standard sequences,
while MRE requires dedicated hardware (mechanical wave
transducer) and sequences. Disadvantages of texture-based
methods are the need for intravenous access and injection of
contrast agents, including two agents for the CCE technique
described here. Also, visualization of subtle reticulations
associated with early fibrosis is sensitive to patient motion;
consequently we obtained four CCE image sets in separate
breath-holds, to ensure that at least one set was motion-
free. As motion correction/minimization techniques become
more robust and clinically available, it may be possible to
acquire images during free breathing with higher signal-to-
noise ratio and spatial resolution.
A limitation of this study is the use of single liver biopsy
as the reference standard. A typical core biopsy (∼30mm3)
samples only 1/50,000 of the liver and is significantly smaller
than the imaging ROI (>400mm3) used in the texture
analysis. Also, biopsied sites are difficult to colocalize with
imaging ROIs, which is relevant because the severity of
fibrosis can be heterogeneous across the liver. An error fre-
quency of up to 33%has been reported for differences in≥ one
fibrosis stage and cirrhosis may be missed in 10–30% of
blind biopsies [40]. Thus even a “perfect” fibrosis prediction
methodmay have onlymoderate observed accuracy in binary
classification if single-biopsy histology is used as the refer-
ence. Obtaining multiple biopsies may reduce errors in the
reference standard, but increases the complication risk and
was not feasible in this study. Considering these limitations,
moderate accuracy of CCE MR imaging is appropriate and
expected. Determination of the true accuracy of fibrosis
imaging may require histologic evaluation of larger speci-
mens than those obtained by percutaneous biopsy. Another
consideration for the accuracy of biopsy as the reference
standard is observer bias [10]. To minimize the observer bias
and increase the accuracy of fibrosis staging, this study used
the average Metavir score of three hepatopathologists’ inde-
pendent interpretations as the reference standard. While
averaging of an ordinal fibrosis score is less than ideal, it is
arguably themost valid fibrosis severitymetric available from
a single biopsy specimen. Such a practice is not uncommon in
hepatology literature [41–44]. As average Metavir score is
expected to preserve the rank-order relationship of the fibro-
sis severity, it should be sufficient tomathematically construct
a valid fibrosis prediction model.
While this study suggested a promising indication for
SPIO agents in liver fibrosis imaging, ferumoxides were
withdrawn from the US market in 2009. Recently, another
intravenously injectable SPIO-based drug, ferumoxytol (Fer-
aheme, AMAG Pharmaceuticals, Lexington, MA) has been
FDA-approved for iron-deficiency therapy and early data on
its application as contrast agent for MR imaging are promis-
ing [45]. While this new drug likely has similar negative-
contrast effects in the liver as ferumoxides, further studieswill
be necessary to evaluate its effectiveness in CCE imaging.
In summary, this proof-of-concept prospective study
showed that CCE MR imaging and quantitative texture
analysis may permit noninvasive assessment of liver fibrosis
in HCV-infected adults. MR image texture is a potential
noninvasive biomarker of liver fibrosis and, with further tech-
nical refinement and validation, may provide a new tool in
clinical management and research in HCV-infected patients.
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